Management of Genital Warts on Labia Majora

Introduction to Treatment Options

The Centers for Disease Control and Prevention recommends offering either patient-applied podofilox 0.5% solution/gel or imiquimod 5% cream as first-line therapy, or provider-administered cryotherapy with liquid nitrogen or TCA 80-90% if the patient prefers in-office treatment, for genital warts on the labia majora 1, 2

The Centers for Disease Control and Prevention suggests applying podofilox 0.5% solution or gel to visible warts twice daily for 3 consecutive days, followed by 4 days off therapy, and repeating this weekly cycle for up to 4 cycles (maximum 4 weeks of treatment) 1, 3
The Centers for Disease Control and Prevention recommends limiting the treatment area to <10 cm² and the total volume to ≤0.5 mL per day when using podofilox 0.5% solution or gel 1, 3
The Centers for Disease Control and Prevention notes that imiquimod 5% cream should be applied once daily at bedtime, 3 times per week, for up to 16 weeks 1, 3

The Centers for Disease Control and Prevention recommends applying cryotherapy with liquid nitrogen every 1-2 weeks until clearance, with an efficacy of 63-88% and recurrence rates of 21-39% 1, 3, 5
The Centers for Disease Control and Prevention suggests using trichloroacetic acid (TCA) 80-90% and applying it sparingly only to warts, allowing it to dry until a white "frosting" develops, with an efficacy of 81% and a recurrence rate of 36% 1, 3, 6

The Centers for Disease Control and Prevention advises choosing a treatment based on patient preference for home vs office treatment, pregnancy status, wart characteristics, and patient ability to identify and reach warts 1, 2
The Centers for Disease Control and Prevention notes that most genital warts respond within 3 months of therapy, and 20-30% of genital warts clear spontaneously within 3 months without treatment 1, 2, 5, 6

The Centers for Disease Control and Prevention warns against using podophyllin resin, podofilox, imiquimod, or sinecatechins during pregnancy 5, 8
The Centers for Disease Control and Prevention advises against exceeding recommended treatment areas (10 cm² for podofilox) or volumes (0.5 mL/day for podofilox) 1, 3, 6

The Centers for Disease Control and Prevention recommends informing patients that treatment removes visible warts but does not eliminate the HPV virus, and that HPV types 6 and 11 cause >90% of genital warts and are low-risk types that do not cause cancer 5, 6, 8
The Centers for Disease Control and Prevention notes that transmission is sexual, but the incubation period is variable (6-10 months median), and determining the source is often difficult 4
The Centers for Disease Control and Prevention advises patients that spontaneous resolution without treatment is possible (20-30% within 3 months), and recurrence is expected in approximately 30% of cases regardless of treatment method 5, 6, 8